Lampalizumab

Names

[ Name ]:
Lampalizumab

Biological Activity

[Description]:

Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Complement System

Research Areas >> Inflammation/Immunology

[Target]

Factor D[1]

[In Vivo]

Lampalizumab 经静脉注射给食蟹猴后，5小时内血清因子D水平增加近10倍，有效中和了其抑制活性[1]。

[References]

[1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475.

[2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7.

Chemical & Physical Properties

[ Molecular Weight ]:
46.96 (kDa)

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.